Diabetes Care Drugs Market to Witness Significant Growth of USD $90.5 Billion with 5.3% CAGR by 2029

 Save 20% on All Global Market Reports With Code ONLINE20 — Gain Insights Into Tariffs, Inflation, and Industry Trends

 

 What Will Be the Forecast Market Size of the Global Diabetes Care Drugs Market by 2029?
 The diabetes care drugs market size has grown strongly in recent years. It will grow from $69.55 billion in 2024 to $73.48 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising global prevalence of diabetes, increasing aging population, sedentary lifestyles and poor dietary habits, rising obesity rates, and growing adoption of personalized medicine.
 
 The diabetes care drugs market size is expected to see strong growth in the next few years. It will grow to $90.50 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to emergence of biosimilar insulins, development of combination therapies and fixed-dose formulations, increasing focus on continuous glucose monitoring and closed-loop systems, and rising awareness and prevention programs targeting prediabetes. Major trends in the forecast period include integration of continuous glucose monitoring with smart drug delivery, adoption of digital patient engagement platforms, wearable drug delivery devices, advancement in peptide or polymer-based sustained-release formulations, and integration of pharmacogenomics for personalized dosing.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=25748&type=smp
 
 What Are the Major Drivers Influencing the Diabetes Care Drugs Market?
 The increasing number of diabetic patients is expected to propel the growth of the diabetes care drugs market going forward. Diabetic patients refer to individuals who have been diagnosed with diabetes mellitus, a chronic medical condition that affects how the body processes blood sugar (glucose). The increasing number of diabetic patients is mainly due to unhealthy diets and sedentary lifestyles, as they promote obesity and insulin resistance. Diabetes care drugs help diabetic patients manage blood glucose levels effectively, making them vital for controlling type 1 and type 2 diabetes. They prevent complications by stabilizing sugar levels, improving overall health, and improving quality of life. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the increasing number of diabetic patients is driving the growth of the diabetes care drugs market. 
 
 Which Segment Holds the Largest Share in the Diabetes Care Drugs Market?
 The diabetes care drugs market covered in this report is segmented — 
 
 1) By Drug Class: Insulin, Biguanides, Sulfonylureas, Dipeptidyl Peptidase (DPP)-4 Inhibitors, Sodium-Glucose Co-Transporter (SGLT)-2 Inhibitors, Glucagon-Like Peptide (GLP)-1 Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors
 2) By Formulation Type: Tablets, Injections, Solutions, Gels, Extended-Release Formulations
 3) By Administration Route: Oral, Injectable, Inhalable
 4) By Condition: Diabetes Type 1, Diabetes Type 2
 5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
 
 Subsegments:
 1) By Insulin: Rapid-acting insulin, Short-acting insulin, Intermediate-acting insulin, Long-acting insulin, Pre-mixed insulin
 2) By Biguanides: Metformin Immediate Release (IR), Metformin Extended Release (ER)
 3) By Sulfonylureas: First-generation sulfonylureas, Second-generation sulfonylureas
 4) By Dipeptidyl Peptidase (DPP)-4 Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin
 5) By Sodium-Glucose Co-Transporter (SGLT)-2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin
 6) By Glucagon-Like Peptide (GLP)-1 Receptor Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide
 7) By Thiazolidinediones (TZDs): Pioglitazone, Rosiglitazone
 8) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol
 
 Which Emerging Trends Are Driving the Diabetes Care Drugs Market?
 Major companies operating in the diabetes care drugs market are focusing on developing advanced treatments, such as fixed-ratio combination therapies, to improve glycemic control, enhance patient adherence, and simplify treatment regimens. Fixed-ratio combination therapies refer to medications that combine two complementary antidiabetic agents in a single injection, offering a more convenient and effective approach to managing diabetes. For instance, in April 2024, Sanofi SA, a France-based pharmaceutical company, launched Soliqua, a once-daily fixed-ratio combination of insulin glargine and lixisenatide specifically designed for adults with type 2 diabetes and obesity. Soliqua combines long-acting insulin glargine, which provides steady fasting glucose control, with lixisenatide, a GLP-1 receptor agonist. This combination enhances glucose-dependent insulin secretion, suppresses glucagon production, and slows gastric emptying to reduce post-meal blood sugar levels, thereby offering comprehensive daily glycemic management. The launch of Soliqua aims to simplify diabetes management, improve glycemic control, and enhance patient adherence by decreasing the need for multiple daily injections and minimizing potential side effects such as hypoglycemia and weight gain.
 
 Which Major Companies Are Operating in the Diabetes Care Drugs Market?
 Major companies operating in the diabetes care drugs market are Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GSK plc, Medtronic plc, Eli Lilly and Company, Teva Pharmaceuticals Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories, Cipla Limited, Lupin Limited, Takeda Pharmaceutical Company Limited, Biocon Limited, Glenmark Pharmaceuticals Limited, Insulet Corporation, Torrent Pharmaceuticals Ltd., Hanmi Pharmaceutical Limited, Hualan Biological, Wockhardt, Mitsubishi Tanabe Pharma, Gan & Lee Pharmaceuticals, DiogenX, Oramed Pharmaceuticals, Apotex. 
 
 Get the full diabetes care drugs market report here:
 https://www.thebusinessresearchcompany.com/report/diabetes-care-drugs-global-market-report
 
 Which Region Is Expected to Lead the Diabetes Care Drugs Market by 2029?
 North America was the largest region in the diabetes care drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes care drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company